IMV Inc.
IMV
Rankning i aktier
#35056
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Aktiekurs
$0.82959892
Senast synkroniserad: 2023-05-23
Marknadsvärde
$4.16M
Förändring (1 dag)
-0.04%
Förändring (1 år)
82,959,792.06%
Land
CA
Handel IMV Inc. (IMV)
Kategori
Healthcare
Aktiekurshistorik för IMV Inc. (IMV)
Högsta slutkurs: $0.00 den 2024-04-01
Lägsta slutkurs: $2.79 den 2009-10-01
Lägsta slutkurs: $2.79 den 2009-10-01
Aktiekurshistorik för IMV Inc. från 2009 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2024 | -99.62% |
| 2023 | -99.90% |
| 2022 | -80.41% |
| 2021 | -58.37% |
| 2020 | 14.77% |
| 2019 | -48.18% |
| 2018 | 1.97% |
| 2017 | 209.96% |
| 2016 | -4.32% |
| 2015 | -11.63% |
| 2014 | 46.23% |
| 2013 | 3.39% |
| 2012 | 10.27% |
| 2011 | -50.45% |
| 2010 | -42.36% |
| 2009 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $535.81 | 25.65% |
US
|
|
| $188.41 | 601.69% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $890.95 | 9.43% |
NL
|
